Qubit Pharmaceuticals and Sorbonne University Unveil FeNNix-Biol
Qubit Pharmaceuticals, a Sorbonne University spin-off, has announced a major leap in pharmaceutical AI with the launch of FeNNix-Biol—an advanced model designed for molecular simulation with quantum-level accuracy. Developed in collaboration with France’s Sorbonne University, the model is poised to transform drug discovery with unprecedented speed and precision.
FeNNix-Biol is engineered to simulate molecular interactions and dynamic behavior, surpassing traditional drug modeling systems. It achieves this while remaining both cost effective and scalable, according to its developers.
Trained on the World’s Most Accurate Molecular Dataset
To build FeNNix-Biol, researchers relied on a newly developed molecular chemistry database. This extensive dataset was created using high-performance computing (HPC) resources from Genci, EuroHPC, and the Argonne National Laboratory in the US.
The database includes millions of biomolecular building blocks. By learning from this diverse and detailed dataset, the AI system can understand the laws of physics and chemistry and simulate the structure and reactivity of biomolecules accurately.
Also read: OpenAI Launches Codex, an AI Coding Agent
Unlike many existing simulation models, FeNNix-Biol accounts for chemical reactivity—a key factor in determining how potential drugs interact with their biological targets.
Going Beyond AlphaFold in Drug Design
While AlphaFold made headlines for predicting static protein structures, FeNNix-Biol addresses a critical limitation. Proteins evolve over time, and their interactions with drug candidates are dynamic. This behavior is essential to simulate if drug responses are to be predicted accurately.
FeNNix-Biol is designed to capture these changing molecular structures, offering a more complete simulation of drug-target interactions. It enables more effective modeling for complex diseases such as cancer and chronic inflammation, where conventional approaches fall short.
Targeting the Toughest Pharmaceutical Challenges
Founded in 2020, Qubit Pharmaceuticals focuses on discovering new drugs through simulation and quantum-accelerated modeling. With FeNNix-Biol, the company is targeting difficult therapeutic areas where existing drugs are ineffective or unavailable.
By combining deep learning with HPC and quantum computing, Qubit Pharmaceuticals is setting new standards in computational drug discovery.
